Press Releases
 
Dilated Cardiomyopathy Therapeutics Market Is Expected To Reach US$ xx Mn By 2026

Dilated Cardiomyopathy Therapeutics Market Is Expected To Reach US$ xx Mn By 2026

United States, 11 February 2019 -- Dilated Cardiomyopathy Therapeutics Market Is Expected To Reach US$ xx Mn By 2026

The latest market report published by Credence Research, Inc. “Global Dilated Cardiomyopathy Therapeutics Market - Growth, Future Prospects, Competitive Analysis, 2018 - 2026,” the global dilated cardiomyopathy therapeutics market was valued at US$ xx Mn in 2017, and is expected to reach US$ xx Mn by 2026, expanding at a CAGR of 4.7% from 2018 to 2026.

Browse the full report Dilated Cardiomyopathy Therapeutics Market - Growth, Future Prospects, Competitive Analysis, 2018 – 2026 report at https://www.credenceresearch.com/report/dilated-cardiomyopathy-therapeutics-market

Market Insights

Dilated cardiomyopathy is a critical heart complication characterized by the enlargement of the left ventricular heart muscles, eventually resulting in decreased pumping of blood. The clinical manifestation of dialted cardiomyopathy are sudden death, cardiac arrhythmias and blood clots. It affects to people in age group between 20 to 50. It is more prevalent in the men in comparison to women. Congenital heart defects in the newborn are also reported worldwide. They early symptoms are fatigue, breathlessness, swelling in legs, ankles and feet. The best preventive measure is to adopt a healthy lifestyle and avoid drinking, smoking & substance abuse.

Currently drug class segment is dominating the treatment segment for dialted cardiomyopathy therapeutics market. The key features promoting the dominance of drug class are excellent clinical outcomes and satisfactory patient compliance. ACE inhibitors are the drug of first choice owing to its ability to relax heart muscles by promoting peripheral vascular blood pooling. Angiotensin receptor blockers are prescribed in combination with diuretics to reduce left ventricular muscle extension and fluid formation in lungs and kidneys. They are recommended to patients showing low tolerance to ACE inhibitors. Beta blockers and anticoagulants are given to reduce pressure on left ventricular muscles and prevent blood clotting in narrow blood vessels of heart. Implantable devices such as heart pumps and biventricular pacemakers are gaining increasing demand due to side effects associated with drug therapy and prolonged benefits of implantable devices.

According to the statistics presented by the Center for Disease Control and Prevention (CDC) in United States, annually 610,000 people die due to heart disease. Increasing public health awareness and affordable reimbursement scenario drive the dilated cardiomyopathy therapeutics market growth in North America. Effective treatment guidelines stipulated by the European Medical Agency (EMA) and domicile of key players such as t2cure GmbH, Merck & Co., Inc., and GlaxoSmithkline Plc etc. drive the market growth in European Union region. Asia Pacific is set to witness outstanding growth during the forecast period 2018 to 2026 on account of rising prevalence of congestive heart failure and enhanced government funding in developing healthcare infrastructure. Moreover rise in medical tourism due to affordable treatment pertaining to heart complications drive the dilated cardiomyopathy therapeutics market growth in Asia Pacific region. Middle East & Africa and Latin America provide a tremendous business expansion opportunity by establishment of retail outlets of key players and capitalizing the untapped market in remote areas.

Pharmaceutical companies spearheading the dilated cardiomyopathy therapeutics market are Aastrom Biosciences, Capricor Therapeutics, GlaxoSmithkline Plc, Johnson and Johnson, Kasiak Research Pvt. Ltd., Merck & Co., Inc., MyoKardia, Pfizer, Inc., t2cure, GmbH, Teva Pharmaceutical Industries, ZensunSci & Tech.

Key Market Movements:

Rising prevalence of congestive heart failure throughout the globe
Increasing public health awareness and affordable reimburment scenario drive the dilated cardiomyopathy therapeutics market
Promising drug pipeline in phase III clinical trials such as ARRY-371797, ixCELL-DCM and enalapril orodispersible minitablets

# # #


Document Attached Image Attached Download file at: 95103
(Right click and save file to download.)

Submitted by Acute Market Reports, Acute Market Research on Monday, 11 February 2019 at 4:42 PM
Category: Business
 
Related News

Why You need to Buy Aged Gmail Accounts
Thursday, 21 Feb 2019

Benefits of Google Reviews For SEO
Thursday, 21 Feb 2019

Woodwork Services from Korck Components
Thursday, 21 Feb 2019

The Significance of Google Reviews
Thursday, 21 Feb 2019

The Health Benefits of Marijuana
Thursday, 21 Feb 2019

Related Events

Palo Alto Networks: OETC Consortium (IntegratED 2019)
Wednesday, 20 Feb 2019

Palo Alto Networks: Presidio Security Operating Platform UTD
Wednesday, 20 Feb 2019

BCG DV Imagines
Friday, 22 Feb 2019

Palo Alto Networks: California Public Sector CIO Academy
Monday, 25 Feb 2019

World Exchange Congress 2019
Tuesday, 26 Feb 2019

Latest News

Why You need to Buy Aged Gmail Accounts
Thursday, 21 Feb 2019

Benefits of Google Reviews For SEO
Thursday, 21 Feb 2019

Woodwork Services from Korck Components
Thursday, 21 Feb 2019

The Significance of Google Reviews
Thursday, 21 Feb 2019

Antiulcerant Drugs Market Latest Report with Forecast to 2026
Thursday, 21 Feb 2019

 
Want to get your press releases, event listings, and job ads on Scoopasia? Register now for a FREE account or login if you already have one!
Scoopasia v1.0b. Copyright © 2019
Today is Thursday, 21 February 2019

About Scoopasia | FAQ | Privacy Policy | Contact Us

Press Releases
Event Listings
Job Listings
Arts & Entertainment
Architecture & Construction
Automotive & Travel
Business
Consumer Technology
Economy
Education
Enterprise Technology
Food & Fashion
Government & Policy
Health Care & Medical
Legal/Law
News & Media
Religion
Science & Research
Sports & Fitness
Login / Register
Get Scoopasia through RSS Feeds & Email Notifications!


Journalist's Toolbox
Hello journalist, welcome to Scoopasia--a powerful online resource for media information in Asia. Scoopasia has press releases and media events for every beat and industry. All content on Scoopasia is 100% FREE. You don't even need to login!

  • Scoop Line
    (Instant Information Request)
    The easiest way to ask questions and request information from the PR community.


  • Advanced Search
    Drill down, dig deep, for media information the way you want it.

  • Journalist's Resources
    Resources and tools you can't do without.

  • PR Tools
    Scoopasia Blog Search
    Search the largest handpicked collection of Asia's most prominent and influential blogs.


    Resources
  • PR Bookmarks
  • Web 2.0 Bookmarks
  • Media Bookmarks

    More Coming Soon...

  • Upcoming Events
  • Stoller's Comprehensive Tutorial in MSK Imaging
  • Recruiting Trends and Talent Tech LIVE! 2019
  • International Conference on Advanced Technologies And Treatments for Diabetes
  • Palo Alto Networks: OETC Consortium (IntegratED 2019)
  • Strategy for Directors Course in London

  • Latest Jobs
    Sorry, there are currently no entries posted here.